Modern treatment for colchicine-resistant familial Mediterranean fever

Download in PDF

The authors report a case of familial Mediterranean fever (FMF) and review a concept of autoinlammatory diseases. Colchicine remains a mainstay of treatment for FMF given its efficacy in prevention of abdominal pain and development or progression of AA-amyloidosis. However, 15 to 20% of patients with FMF do not respond to colchicine and require treatment with modern biologic agents such as canakinumab that blocks interleukin-1.

Key words

Autoinflammatory diseases, familial Medi terraneanfever, colchicine, interleukin-1 blockers, canakinu mab.